Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Forster

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 18, 2006
Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized studyEugene V McCloskey, Monique Beneton, Diane Charlesworth, et al.
Clinical Lung Cancer|May 26, 2021
A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung CancerLauren Averett Byers, Alejandro Navarro, Eric Schaefer, et al.
Investigational New Drugs|March 11, 2021
Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I studyMaría Eugenia Olmedo, Martin Forster, Victor Moreno, et al.
Cancers|September 13, 2025
Predictors and Outcomes of Non-Small Cell Lung Carcinoma Patients Following Severe Immune Checkpoint Inhibitor Toxicity: A Real-World UK Multi-Centre StudyUmair Mahmood, Eleni Josephides, Meenali Chitnis, et al.
Therapeutic Advances in Medical Oncology|November 12, 2020
COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort studyValerie E Crolley, Daire Hanna, Nalinie Joharatnam-Hogan, et al.
European Journal of Cancer (Oxford, England : 1990)|December 18, 2024
Hydroxychloroquine in combination with platinum doublet chemotherapy as first-line treatment for extensive-stage small cell lung cancer (Study 15): A randomised phase II multicentre trialSiow Ming Lee, Madeleine Hewish, Samreen Ahmed, et al.
Oral Oncology|August 13, 2018
Frequent HPV-independent p16/INK4A overexpression in head and neck cancerMatt Lechner, Ankur R Chakravarthy, Vonn Walter, et al.
Genome Medicine|May 31, 2013
Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumorsMatthias Lechner, Garrett M Frampton, Tim Fenton, et al.
The Lancet. Oncology|May 19, 2022
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 studyMarjorie G Zauderer, Peter W Szlosarek, Sylvestre Le Moulec, et al.
Trials|January 14, 2024
CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancerHisham Mehanna, Piers Gaunt, Anthony Kong, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 18, 2006
Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized studyEugene V McCloskey, Monique Beneton, Diane Charlesworth, et al.
Clinical Lung Cancer|May 26, 2021
A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung CancerLauren Averett Byers, Alejandro Navarro, Eric Schaefer, et al.
Investigational New Drugs|March 11, 2021
Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I studyMaría Eugenia Olmedo, Martin Forster, Victor Moreno, et al.
Cancers|September 13, 2025
Predictors and Outcomes of Non-Small Cell Lung Carcinoma Patients Following Severe Immune Checkpoint Inhibitor Toxicity: A Real-World UK Multi-Centre StudyUmair Mahmood, Eleni Josephides, Meenali Chitnis, et al.
Therapeutic Advances in Medical Oncology|November 12, 2020
COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort studyValerie E Crolley, Daire Hanna, Nalinie Joharatnam-Hogan, et al.
European Journal of Cancer (Oxford, England : 1990)|December 18, 2024
Hydroxychloroquine in combination with platinum doublet chemotherapy as first-line treatment for extensive-stage small cell lung cancer (Study 15): A randomised phase II multicentre trialSiow Ming Lee, Madeleine Hewish, Samreen Ahmed, et al.
Oral Oncology|August 13, 2018
Frequent HPV-independent p16/INK4A overexpression in head and neck cancerMatt Lechner, Ankur R Chakravarthy, Vonn Walter, et al.
Genome Medicine|May 31, 2013
Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumorsMatthias Lechner, Garrett M Frampton, Tim Fenton, et al.
The Lancet. Oncology|May 19, 2022
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 studyMarjorie G Zauderer, Peter W Szlosarek, Sylvestre Le Moulec, et al.
Trials|January 14, 2024
CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancerHisham Mehanna, Piers Gaunt, Anthony Kong, et al.
Pageof 9